Neoadjuvant immunochemotherapy in potentially resectable small cell lung cancer: a real-world retrospective analysis

Our findings suggest that neoadjuvant immunotherapy combined with chemotherapy followed by surgery may provide a survival benefit over chemotherapy alone in the treatment of resectable SCLC. The combined treatment approach significantly improved the pCR rates and DFS of the patients with resectable SCLC. While our study highlights the potential of this approach, further prospective multi-center studies need to be conducted to validate these findings and explore biomarkers for personalized treatment strategies.